FIG 11.

Suppression of RCC-mediated EC survival and tumor formation by dovinitib treatment. (A) Coculture assay testing the ability of dovitinib to suppress EC survival by the different RCC lines. Data are means ± SEM. n = 4 for TG144, n = 4 for TG158, n = 7 for TG206, n = 4 for TG127, n = 6 for TG169, n = 12 for TG121, n = 4 for T256, n = 3 for T241, n = 4 for T258, n = 4 for PF22, n = 4 for PF114, and n = 2 for T239. (B) Tumor take rates of sunitinib-resistant tumors upon dovitinib treatment. See Table 7 for more details. (C) Bright-field and fluorescence images of a sunitinib-resistant RCC line (T258) after treatment with Ve, Su, or Do. *, P < 0.05; **, P < 0.01, ***, P < 0.001.